Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea.
Department of Pharmacology, School of Dentistry, Brain Science and Engineering Institute, Kyungpook National University, Daegu 41940, Korea.
Molecules. 2020 Oct 12;25(20):4641. doi: 10.3390/molecules25204641.
Glioblastoma (GBM) is aggressive malignant tumor residing within the central nervous system. Although the standard treatment options, consisting of surgical resection followed by combined radiochemotherapy, have long been established for patients with GBM, the prognosis is still poor. Despite recent advances in diagnosis, surgical techniques, and therapeutic approaches, the increased patient survival after such interventions is still sub-optimal. The unique characteristics of GBM, including highly infiltrative nature, hard-to-access location (mainly due to the existence of the blood brain barrier), frequent and rapid recurrence, and multiple drug resistance mechanisms, pose challenges to the development of an effective treatment. To overcome current limitations on GBM therapy and devise ideal therapeutic strategies, efforts should focus on an improved molecular understanding of GBM pathogenesis. In this review, we summarize the molecular basis for the development and progression of GBM as well as some emerging therapeutic approaches.
胶质母细胞瘤（GBM）是一种侵袭性的恶性肿瘤，位于中枢神经系统内。尽管手术切除联合放化疗等标准治疗方案早已确立用于 GBM 患者，但预后仍较差。尽管近年来在诊断、手术技术和治疗方法方面取得了进展，但此类干预后患者的生存率仍不理想。GBM 的独特特征，包括高度浸润性、难以到达的位置（主要由于血脑屏障的存在）、频繁且快速的复发以及多种药物耐药机制，给治疗的发展带来了挑战。为了克服目前 GBM 治疗的局限性并设计理想的治疗策略，应致力于提高对 GBM 发病机制的分子认识。在这篇综述中，我们总结了 GBM 发生和进展的分子基础以及一些新出现的治疗方法。
